ENOV - This Analyst Selects Enovis As Top Pick For 2024: Spotlight On EMPOWR Revision Launch | Benzinga
Needham analyst Mike Matson reiterated the Buy rating on Enovis Corporation (NYSE: ENOV), raising the price target to $70 from $62.
The analyst selected ENOV as his top pick for 2024 and added it to the Needham Conviction List, replacing Boston Scientific Corporation (NYSE: BSX).
Matson foresees multiple significant top and bottom line growth drivers in 2024, including the EMPOWR Revision launch, the ARVIS 2.0 launch, and the Lima acquisition.
Additionally, the analyst sees continued EBITDA margin improvement from ENOV's ...